Product image of Linagliptin Krka (Linagliptin) supplied by GNH India

Linagliptin Krka

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Krka (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Krka, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH India supplies Linagliptin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is indicated for the management of type 2 diabetes mellitus, acting on the incretin pathway to lower blood glucose.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose when used with diet and exercise.
  • Type 2 diabetes mellitus (combination therapy): adds glucose‑lowering effect when combined with other oral antidiabetics or insulin.
  • Type 2 diabetes mellitus with renal impairment: provides effective glycaemic control without dose adjustment in patients with reduced kidney function.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of endogenous incretin hormones (GLP‑1 and GIP). Elevated incretin levels enhance glucose‑dependent insulin secretion and suppress glucagon release, resulting in improved post‑prandial and fasting blood glucose levels.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract infection symptoms.
  • Headache: transient mild to moderate pain.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal upset: nausea, abdominal discomfort.
  • Back pain: musculoskeletal discomfort.
  • Arthralgia: joint pain.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: rash, angioedema, anaphylaxis.
  • Hepatic injury: jaundice, elevated liver enzymes.
  • Bullous pemphigoid: blistering skin disorder.
  • Hypersensitivity syndrome: fever, rash, organ involvement.
  • Acute renal failure: abrupt decline in kidney function.

Precautions & Warnings

Linagliptin should be used with consideration of the following precautions:

  • Renal function assessment: evaluate renal status before initiation.
  • Hepatic impairment: monitor liver enzymes in patients with liver disease.
  • Cardiovascular disease: use cautiously in patients with unstable heart conditions.
  • Pregnancy and lactation: avoid unless benefits outweigh potential risks.
  • Concomitant insulin or sulfonylureas: monitor for hypoglycaemia.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin may interact with several medicines. Review the following categories:

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase linagliptin exposure.
  • Co‑administration with another DPP‑4 inhibitor: provides no additional benefit and raises risk of adverse events.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed.
  • Rifampin: may reduce linagliptin plasma concentrations.
  • Diuretics: may affect glucose control; monitor blood glucose.
  • Digoxin: slight increase in digoxin levels; observe for toxicity.

Frequently Asked Questions

Linagliptin Krka contains the active ingredient linagliptin, a DPP‑4 inhibitor indicated for improving blood glucose control in adults with type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents.

Linagliptin selectively blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood glucose levels.

The prescribed dose of Linagliptin Krka is determined by the treating healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the exact dosing instructions provided by their prescriber.

The safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same mechanism of action as other DPP‑4 inhibitors but differs in its pharmacokinetic profile; it is primarily eliminated via the entero‑hepatic route and does not require dose adjustment in renal impairment, which can be an advantage over some alternatives.

Linagliptin Krka tablets should be stored at ambient temperature, below 25 °C, in the original blister pack, protected from moisture and direct sunlight to maintain product stability.

Linagliptin Krka is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not chewed or crushed.

Serious risks, although rare, include pancreatitis, severe allergic reactions such as anaphylaxis, hepatic injury, and bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of liver dysfunction.

Linagliptin is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is also advised for individuals with a history of pancreatitis or severe hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT